BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
58.19
+1.04 (1.82%)
Feb 6, 2026, 2:19 PM EST - Market open
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 21 analysts that cover BioMarin Pharmaceutical stock have a consensus rating of "Buy" and an average price target of $89.86, which forecasts a 54.43% increase in the stock price over the next year. The lowest target is $60 and the highest is $126.
Price Target: $89.86 (+54.43%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 6 | 6 |
| Buy | 11 | 9 | 9 | 8 | 8 | 9 |
| Hold | 7 | 7 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 22 | 19 | 19 | 20 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $122 → $84 | Buy | Maintains | $122 → $84 | +44.35% | Feb 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold → Strong Buy Upgrades $84 → $98 | Hold → Strong Buy | Upgrades | $84 → $98 | +68.41% | Jan 20, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $80 → $100 | Strong Buy | Maintains | $80 → $100 | +71.85% | Dec 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $55 → $60 | Hold | Maintains | $55 → $60 | +3.11% | Dec 22, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $82 → $60 | Buy → Hold | Downgrades | $82 → $60 | +3.11% | Dec 3, 2025 |
Financial Forecast
Revenue This Year
3.24B
from 2.85B
Increased by 13.53%
Revenue Next Year
3.55B
from 3.24B
Increased by 9.69%
EPS This Year
2.70
from 2.21
Increased by 22.18%
EPS Next Year
4.43
from 2.70
Increased by 64.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.4B | 4.0B | ||||
| Avg | 3.2B | 3.6B | ||||
| Low | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 18.0% | 23.3% | ||||
| Avg | 13.5% | 9.7% | ||||
| Low | 8.1% | -2.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.92 | 6.97 | ||||
| Avg | 2.70 | 4.43 | ||||
| Low | 1.03 | 3.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 77.4% | 158.5% | ||||
| Avg | 22.2% | 64.4% | ||||
| Low | -53.4% | 23.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.